DanCann Pharma A/S: Germany trends – prescriptions for medicinal cannabis positively influenced by new legalization

COPENHAGEN, Denmark, 14 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, announces key insights into the recent legalization of cannabis in Germany ("CanG"), which came into effect on April 1, 2024.

Key highlights from CanG:

• Declassification: Cannabis is no longer classified as a narcotic but as a regular (off-label-use) medicine.
• Elimination of risk assessment: No longer required to assess risks such as possible addiction when prescribing medicinal cannabis.
• Simplified prescription process: Abolition of narcotic prescription procedures.
• Reduced documentation requirements: Reduction in documentation and security measures obligations for retailers and pharmacies.
• Telemedicine facilitation: Telemedicine becomes possible.
• Projected prescription surge: Initial data suggests an explosion in the number of prescriptions of medicinal cannabis.

The implementation of the CanG law has revolutionized the medicinal cannabis landscape in Germany, presenting new opportunities for patients and the market. The introduction of this legislation has substantially reduced bureaucratic hurdles, resulting in an upsurge in the number of patients accessing medicinal cannabis.

Regulatory changes and impact on patients

A pivotal aspect of the CanG legislation is the removal of cannabis from the list of controlled substances. This revision has markedly streamlined the process of prescribing medicinal cannabis, aligning it with the prescription of other medications such as painkillers and antidepressants. Previously, doctors encountered numerous bureaucratic impediments throughout the supply chain, which have now been minimized.

Presently, patients seeking medicinal cannabis only need to undergo a brief initial consultation, following which they receive a "purchase certificate," enabling them to procure medicinal cannabis from their local dispensary.

Furthermore, individuals no longer need to physically visit their general practitioner to obtain a medicinal cannabis prescription. Through designated websites, patients can acquire a medicinal cannabis prescription with just a few clicks, bypassing the need for a consultation with a physician. By completing an online questionnaire, patients can indicate their symptoms, such as back pain or insomnia, and receive their prescription via email.

Telemedicine boom and medicinal cannabis availability

Following the reclassification of cannabis on April 1, 2024, numerous companies have commenced offering online consultations. Prescribed medications are then delivered directly to the patient's residence or to a selected pharmacy.

According to several German national sources, including Sanity Group and Cannamedical Pharma, there has been a substantial increase in the number of patients, with reports of 70-100,000 new patients in the first month alone since the new legislation took effect on April 1, 2024.

Prospects for Denmark:

The developments in Germany are viewed positively by DanCann Pharma, where CEO Jeppe Krog Rasmussen comments:

"The indications and trends we observe in response to the new legislation (CanG) suggest that there is more to come. We are tirelessly advocating for our own conditions here in Denmark, including our efforts in public affairs for better conditions for the whole ecosystem (patients, prescribers and industry). Germany certainly sets a vision for this and how we can streamline the bureaucratic processes involved, particularly in the prescription of medicinal cannabis. As stated previously and still holds true; Germany can – and will – play a decisive role and initiate a domino effect for the rest of Europe over time. This not only signifies progress for German patients but also holds promise for Danish patients if we draw insights from Germany’s approach."

For media inquiries or further information, please contact:

Jeppe Krog Rasmussen, CEO

DanCann Pharma A/S

Email: jkr@dancann.com

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

For more information, please visit: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.